Guttman-Yassky E, Irvine A, Simpson E, Gooderham M, Weidinger S, Spelman L, Silverberg J, Crane H, Elmaraghy H, DeLuca-Carter L, Buziqui Piruzeli ML, Hu C, Pierce E, Agell H, Thaçi D. Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe ​ Atopic Dermatitis: Results Up to 3 Years From ADjoin. J of Skin [Internet]. 2025Jan.13 [cited 2025Mar.12];9(1):s510. Available from: https://skin.dermsquared.com/skin/article/view/3153